Investigational agents that protect pancreatic islet β-cells from failure

Bibliography

• PORTE D Jr: 13-cells in Type II diabetes. Diabetes (1991) 40:166–180.
   PubMed Web of Science ®Google Scholar
• WEYER C, BOGARDUS C, MOTT DM, RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J. Clin. Invest. (1999) 104:787–794.
   PubMed Web of Science ®Google Scholar
• TURNER RC: The UK Prospective Diabetes Study. A review. Diabetes Care (1998) 21\(Suppl. 3):C35–C38.
   Google Scholar
• LEAHY JL, COOPER HE, DEAL DA, WEIR GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions.. Invest. (1986) 77:908–915.
   Google Scholar
• DAVALLI AM, RICORDI C, SOCCI C et al.: Abnormal sensitivity to glucose of human islets culture in a high glucose medium: partial reversibility afer an additional culture in a normal glucose medium. J. Clin. Endocrinol Metab. (1991) 72:202–208.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, ZHANG HJ, PYZDROWSKI KL, WALSETH TF: Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. Clin. Invest. (1992) 90:320–325.
   Google Scholar
• ZRAIKA S, DUNLOP M, PROIETTO J, S: Effects of free fatty acids on insulin secretion in obesity.. Rev (2002) 3:103–112.
   Google Scholar
• •An excellent review of the deleterious effects of fatty acids on lei-cell function.
   Google Scholar
• PAOLISSO G, GAMBARDELLA A, AMATO L et al.: Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia (1995) 38:1295–1299.
   PubMed Web of Science ®Google Scholar
• ZHOU Y-P, GRILL VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J. Clin. Invest. (1994) 93:870–876.
   PubMed Web of Science ®Google Scholar
• ZHOU YP, PRIESTMAN DA, RANDLE PJ, GRILL VE: Fasting and decreased B cell sensitivity: important role for fatty acid-induced inhibition of PDH. Am. J. Physiol (1996) 270:E988–E994.
   PubMed Web of Science ®Google Scholar
• ZHOU YP, BERGGREN PO, GRILL V: A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of 0-cell dysfunction in the obese diabetic db/db mouse. Diabetes (1996) 45:580–586.
   PubMed Web of Science ®Google Scholar
• BRUNT,-JEANNET F, CORKEY BE, PRENTKI M: Long-chain fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreatic 0-cell line INS-1. Diabetes (1997) 46:393–400.
   PubMedGoogle Scholar
• LAMELOISE N, MUZZIN P, M,-JEANNET F: Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes (2001) 50:803–809.
   PubMed Web of Science ®Google Scholar
• SHIMABUKURO M, ZHOU YT, M, UNGER RH: Fatty acid-induced 0-cell apoptosis: A link between obesity and diabetes. Proc. Nati Acad. Sri. USA (1998) 95:2498–2502.
   PubMed Web of Science ®Google Scholar
• CNOP M, HANNAERT JC, HOORENS A, EIZIRIK DL, DG: Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes (2001) 50:1771–1777.
   PubMed Web of Science ®Google Scholar
• •An important study showing the mechanism of fatty acid-induced 13-cell dysfunction.
   Google Scholar
• ZRAIKA S, DUNLOP ME, PROIETTO J,ANDRIKOPOULOS S: Elevated SNAP-25 is associated with fatty acid-induced impairment of mouse islet function. Biochem. Biophys. Res. Commun. (2004) 317:472–477.
   PubMed Web of Science ®Google Scholar
• SAITO K, TAKAHASHI T, YAGINUMA N, IWAMA N: Islet morphometry in the diabetic pancreas of man. Tohoku J. Exp. Med. (1978) 125:185–197.
   PubMed Web of Science ®Google Scholar
• BUTLER AE, JANSON J,-WEIR S et al: 13-cell deficit and increased 13-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52:102–110.
   PubMed Web of Science ®Google Scholar
• ••A pivotal study showing decreased islet 13-cell volume in patients with Type 2 diabetes.
   Google Scholar
• SAITO K, YAGINUMA N, T: Differential volumetry of A, B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku Exp. Med. (1979) 129:273–283.
   PubMed Web of Science ®Google Scholar
• ALZAID A, AIDEYAN 0, NAWAZ S: The size of the pancreas in diabetes mellitus. Diabet. Med. (1993) 10:759–763.
   PubMed Web of Science ®Google Scholar
• RENDELL M: The role of sulphonylureasin the management of Type 2 diabetes mellitus. Drugs (2004) 64:1339–1358.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC,-CONNOR E, FOWLER SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl. I Med. (2002) 346:393–403.
   Google Scholar
• •An important study describing the beneficial effects of metformin in subjects who are at risk of developing Type 2 diabetes.
   Google Scholar
• SONG S, ANDRIKOPOULOS S, FILIPPIS C et al.: Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. Am. I Physiol Metab. (2001) 281:E275–E282.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, RABASA-LHORET R:Prevention of Type 2 diabetes: insulin resistance and 13-cell function. Diabetes (2004) 53\(Suppl. 3):S34–S38.
   Google Scholar
• LUPI R, DEL GUERRA S, TELLINI C et al: The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur. Pharmacol (1999) 364:205–209.
   PubMed Web of Science ®Google Scholar
• PATANE G, PIRO S, RABUAZZO AM et al.: Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic 13-cells. Diabetes (2000) 49:735–740.
   PubMed Web of Science ®Google Scholar
• MARCHETTI P, DEL GUERRA S, MARSELLI L et al.: Pancreatic islets from Type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. Metab. (2004) 89:5535–5541.
   Web of Science ®Google Scholar
• KEMP BE, STAPLETON D, CAMPBELL DJ et al.: AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. (2003) 31:162–168.
   PubMed Web of Science ®Google Scholar
• ETO K, YAMASHITA T, MATSUI J et al.:Genetic manipulations of fatty acid metabolism in 13-cells are associated with dysregulated insulin secretion. Diabetes (2002) 51\(Suppl. 3):S414–S420.
   Google Scholar
• LECLERC I, WOLTERSDORF WW, DA SILVA XAVIER G et al.: Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol Endocrinol Metab. (2004) 286:E1023–E1031.
   Google Scholar
• KEFAS BA, CAI Y, KERCKHOFS K et al.:Metformin-induced stimulation of AMP-activated protein kinase in 13-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem. Pharmacol (2004) 68:409–416.
   PubMed Web of Science ®Google Scholar
• OSEI K, GAILLARD T, KAPLOW J, BULLOCK M, SCHUSTER D: Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and Type 2 diabetes. Metabolism (2004) 53:1552–1557.
   PubMed Web of Science ®Google Scholar
• JUHL CB, HOLLINGDAL M, PORKSEN N et al.: Influence of rosiglitazone treatment on 13-cell function in Type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. I Clin. Metab. (2003) 88:3794–3800.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.. Endocrinol Metab. (1997) 82:2108–2116.
   Web of Science ®Google Scholar
• CAVAGHAN MK, EHRMANN DA, BYRNE MM, POLONSKY KS: Treatment with the oral antidiabetic agent troglitazone improves 13-cell responses to glucose in subjects with impaired glucose tolerance.. Invest. (1997) 100:530–537.
   Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic 13-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 51:2796–2803.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC, HAMMAN RE EDELSTEIN SL et al.: Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 54:1150–1156.
   Google Scholar
• ••Findings from the Diabetic PreventionProgram suggesting that TZDs can prevent the progression to Type 2 diabetes.
   Google Scholar
• SMITH SA, PORTER LE, BISWAS N, FREED MI: Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in Type 2.Endocrinol Metab. (2004)89:6048–6053.
   Web of Science ®Google Scholar
• OVALLE F, BELL DS: Effect of rosiglitazone versus insulin on the pancreatic 13-cell function of subjects with Type 2 diabetes. Diabetes Care (2004) 27:2585–2589.
   PubMed Web of Science ®Google Scholar
• WALLACE TM, LEVY JC, DR: An increase in insulin sensitivity and basal 13-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet. Med. (2004) 21:568–576.
   PubMed Web of Science ®Google Scholar
• SCHERNTHANER G, DR, CHARBONNEL B, HANEFELD M, BRUNETTI P: Efficacy and safety of pioglitazone versus metformin in patients with Type 2 diabetes mellitus: a double-blind, randomized trial. I. Clin. Endocrinol Metab. (2004) 89:6068–6076.
   PubMed Web of Science ®Google Scholar
• CHARBONNEL BH, MATTHEWS DR, SCHERNTHANER G, HANEFELD M, BRUNETTI P: A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med. (2005) 22:399–405.
   PubMed Web of Science ®Google Scholar
• TAN MH, BAKSI A, KRAHULEC B et al: Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years patients with Type 2 diabetes. Diabetes Care (2005) 28:544–550.
   Google Scholar
• SREENAN S, STURIS J, PUGH W, BURANT CF, POLONSKY KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol (1996) 271:E742–E747.
   PubMed Web of Science ®Google Scholar
• HIGA M, ZHOU YT, RAVAZZOLA M et al.: Troglitazone prevents mitochondrial alterations, 13-cell destruction and diabetes in obese prediabetic rats. Proc. Natl. Acad. Li. USA (1999) 96:11513–11518.
   PubMed Web of Science ®Google Scholar
• JIA DM, TABARU A, NAKAMURA H et al.: Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Metabolism (2000) 49:1167–1175.
   PubMed Web of Science ®Google Scholar
• FINEGOOD DT, McARTHUR MD, KOJWANG D et al.: 13-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes (2001) 50:1021–1029.
   Google Scholar
• BEALES PE, LIDDI R, GIORGINI AE et al: Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur. Pharmacol (1998) 357:221–225.
   PubMed Web of Science ®Google Scholar
• OGAWA J, TAKAHASHI S, FUJI WARA Tet al: Troglitazone can prevent development of Type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life ScL (1999) 65:1287–1296.
   PubMed Web of Science ®Google Scholar
• HULL RL, SHEN ZP, WATTS MR et al:Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes (2005) 54:2235–2244.
   PubMed Web of Science ®Google Scholar
• LUPI R, DEL GUERRA S, MARSELLI L et al.: Rosiglitazone prevents the of human islet function induced by fatty acids: evidence for a role of PPAR-y2 in the modulation of insulin secretion. Am. Physiol Endocrinol Metab. (2004) 286:E560–E567.
   PubMed Web of Science ®Google Scholar
• YANG L, AN HX, DENG XL, CHEN LL, LI ZY: Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway. Acta Pharmacol SM. (2003) 24:429–434.
   Web of Science ®Google Scholar
• KAWASAKI F, MATSUDA M, KANDA Y, INOUE H, KAKU K: Structural and functional analysis of pancreatic islets by pioglitazone in db/db mice. Am. I Physiol Endocrinol. Metab. (2005) 288:E510–E518.
   PubMed Web of Science ®Google Scholar
• MATSUI J, TERAUCHI Y, KUBOTA N et al.: Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-y-deficient mice on a high-fat diet. Diabetes (2004) 53:2844–2854.
   PubMed Web of Science ®Google Scholar
• ZEENDER E, MAEDLER K, BOSCO D et al.: Pioglitazone and sodium salicylate protect human 13-cells against apoptosis and impaired function induced by glucose and interleukin-10. j Clin. Endocrinol. Metab. (2004) 89:5059–5066.
   PubMed Web of Science ®Google Scholar
• ISHIDA H, TAKIZAWA M, OZAWA S et al.: Pioglitazone improves insulin secretory capacity and prevents the loss of 13-cell mass in obese diabetic db/db mice: possible protection of 13-cells from oxidative stress. Metabolism (2004) 53:488–494.
   PubMed Web of Science ®Google Scholar
• DIANI AR, SAWADA G, WYSE B, MURRAY FT, KHAN M: Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of Type 2 diabetes. Am. J. Physiol Endocrinol Metab. (2004) 286:E116–122.
   PubMed Web of Science ®Google Scholar
• CNOP M, HANNAERT JC, DG: Troglitazone does not protect rat pancreatic 13-cells against free fatty acid-induced cytotoxicity.. Pharmacol (2002) 63:1281–1285.
   Web of Science ®Google Scholar
• ROSEN ED, KULKARNI RN, SARRAF P et al.: Targeted elimination of peroxisome proliferator-activated receptor-y in 13-cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell. Biol. (2003) 23:7222–7229.
   PubMed Web of Science ®Google Scholar
• BAGGIO LL, DRUCKER DJ: Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.. Endocrinol. (2002) 1:117–125.
   Google Scholar
• KNOP FK, VILSBOLL T, LARSEN S et al.: No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean Type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care (2003) 26:2581–2587.
   PubMed Web of Science ®Google Scholar
• EGAN JM, CLOCQUET AR, ELAHI D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to Type 2 diabetes. J. Clin. Endocrinol Metab. (2002) 87:1282–1290.
   PubMed Web of Science ®Google Scholar
• MART A, SALLAS WM, HE YL et al: Vildagliptin, a dipeptidyl peptidase-IV, improves model-assessed 13-cell function in patients with Type 2 diabetes. Gbh Endocrinol. Metab. (2005) 90:4888–4894.
   PubMed Web of Science ®Google Scholar
• NIELSEN LL: Incretin mimetics and DPP-IV inhibitors for the treatment of Type 2 diabetes. Drug Discov. Today (2005) 10:703–710.
   PubMed Web of Science ®Google Scholar
• ••An excellent and concise review of GLP-1analogues and DPP-IV inhibitors, and their clinical trial status.
   Google Scholar
• JUHL CB, SCHMITZ 0, PINCUS S et al: Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness. Diabetologia (2000) 43:583–588.
   PubMed Web of Science ®Google Scholar
• RITZEL R, SCHULTE M, PORKSEN N et al: Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with Type 2 diabetes and impaired glucose tolerance. Diabetes (2001) 50:776–784.
   PubMed Web of Science ®Google Scholar
• QUDDUSI S, VAHL TP, HANSON K, PRIGEON RL, D'ALESSIO DA: Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care (2003) 26:791–798.
   PubMed Web of Science ®Google Scholar
• DEGN KB, JUHL CB, STURIS J et al:One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and 13-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes (2004) 53:1187–1194.
   PubMed Web of Science ®Google Scholar
• KENDALL DM, RIDDLE MC, ROSENSTOCK J et al: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 28:1083–1091.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, RATNER RE, HAN J et al: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care (2005) 28:1092–1100.
   PubMed Web of Science ®Google Scholar
• POON T, NELSON P, SHEN L et al: Exenatide improves glycemic control and reduces body weight in subjects with Type 2 diabetes: a dose-ranging study. 7Ochnol. Then (2005) 7:467–477.
   Google Scholar
• MacDONALD PE, SALAPATEK AM, WHEELER MB: Glucagon-like peptide–1 activation antagonizes voltage-dependent repolarizing K(+) currents in 0-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes (2002) 51 (Suppl. 3):S443–S447.
   Google Scholar
• MacDONALD PE, WANG X, XIA F et al: of rat 0-cell voltage-dependent K.' currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. I Biol. Chem. (2003) 278:52446–52453.
   Google Scholar
• SKOGLUND G, HUSSAIN MA, HOLZ GG: Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes (2000) 49:1156–1164.
   PubMed Web of Science ®Google Scholar
• BRUBAKER PL, DRUCKER DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 145:2653–2659.
   PubMed Web of Science ®Google Scholar
• •A useful review of OLP-1 and its potential therapeutic benefits.
   Google Scholar
• STOFFERS DA, KIEFFER TJ, MA et al.: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes (2000) 49:741–748.
   PubMed Web of Science ®Google Scholar
• PERFETTI R, ZHOU J, DOYLE ME, EGAN JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology (2000) 141:4600–4605.
   PubMed Web of Science ®Google Scholar
• HUT H, WRIGHT C, PERFETTI R: Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes (2001) 50:785–796.
   PubMed Web of Science ®Google Scholar
• ABRAHAM EJ, LEECH CA, LIN JC, ZULEWSKI H, HABENER JF: Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology (2002) 143:3152–3161.
   PubMed Web of Science ®Google Scholar
• TOURREL C, BAILBE D, LACORNE M et al.: Persistent improvement of Type 2 diabetes in the Goto-Kakizaki rat model by expansion of the 0-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes (2002) 51:1443–1452.
   PubMed Web of Science ®Google Scholar
• WANG Q, BRUBAKER PL: Glucagon-likepeptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia (2002) 45:1263–1273.
   PubMed Web of Science ®Google Scholar
• FARILLA L, HUT H, BERTOLOTTO C et al: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology (2002) 143:4397–4408.
   PubMed Web of Science ®Google Scholar
• LI Y, HANSOTIA T, YUSTA B et al.: Glucagon-like peptide-1 receptor signaling modulates 0-cell apoptosis. J. Biol. Chem. (2003) 278:471–478.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, MARTIN J, DOTY T et al: Dipeptidyl peptidase IV inhibitor treatment stimulates 0-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52:741–750.
   PubMed Web of Science ®Google Scholar
• WANG Q, LI L, XU E et al.: Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-113 cells. Diabetologia (2004) 47:478–487.
   PubMed Web of Science ®Google Scholar
• LEUNG PS, CARLSSON PO: Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas (2005) 30:293–298.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, DAHLOF B, SE et al: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. (2003) 139:169–177.
   PubMed Web of Science ®Google Scholar
• ••Outcomes of the LIFE study showingpositive effects of losartan.
   Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• LAU T, CARLSSON PO, LEUNG PS: Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia (2004) 47:240–248.
   PubMed Web of Science ®Google Scholar
• BRASIER AR, PHILIPPE J, DJ, HABENER JF: Novel expression of the angiotensinogen gene in a rat pancreatic islet cell line. Transcriptional regulation by glucocorticoids. J. Biol. Chem. (1986) 261:16148–16154.
   PubMedGoogle Scholar
• TIKELLIS C, WOOKEY PJ, R et al: Improved islet morphology after blockade of the renin- system in the ZDF rat. Diabetes (2004) 53:989–997.
   PubMed Web of Science ®Google Scholar
• •The first study to show that the inhibition of RAS is beneficial to islet function and pathology in an animal model of Type 2 diabetes.
   Google Scholar
• FORBES JM, COOPER ME, MD, THOMAS MC: Role of advanced glycation end products in diabetic nephropathy. I Am. Soc. Nephrol (2003) 14:S254–S258.
   PubMed Web of Science ®Google Scholar
• MATSUOKA T, KAJIMOTO Y, WATADA H et al.: Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells../. Chu. Invest. (1997) 99:144–150.
   PubMed Web of Science ®Google Scholar
• TAJIRI Y, MOLLER C, GRILL V: Longterm effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycation end products inhibits B cell function. Endocrinology (1997) 138:273–280.
   PubMed Web of Science ®Google Scholar
• KAJIMOTO Y, MATSUOKA T, KANETO H et al: Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia (1999) 42:1417–1424.
   PubMed Web of Science ®Google Scholar
• KANETO H, KAJIMOTO Y, J et al.: Beneficial effects of antioxidants in diabetes. Possible protection of pancreatic 0-cells against glucose toxicity. Diabetes (1999) 48:2398–2406.
   Google Scholar
• POITOUT V, OLSON LK, RP: Chronic exposure of f3TC-6 cells to supraphysiological concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J. Chu. Invest. (1996) 97:1041–1046.
   PubMed Web of Science ®Google Scholar
• MORAN A, ZHANG HJ, OLSON K et al.: Differentiation of glucose toxicity from 0-cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J. Chu. Invest. (1997) 99:534–539.
   PubMed Web of Science ®Google Scholar
• MARSHAK S, LEIBOWITZ G, BERTUZZI F et al.: Impaired 0-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes (1999) 48:1230–1236.
   PubMed Web of Science ®Google Scholar
• PIERCY V, TOSELAND CD, TURNER NC: Potential benefit of inhibitors of advanced glycation end products in the progression of Type II diabetes: a study with aminoguanidine in C57/13LKsJ diabetic mice. Metabolism (1998) 47:1477–1480.
   PubMed Web of Science ®Google Scholar
• KOOPTIWUT S, KEBEDE M, ZRAIKA S et al.: High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction.. Endocrinol. (2005) 35:39–48.
   Web of Science ®Google Scholar
• EVANS JL, GOLDFINE ID, BA, GRODSKY GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and 0-cell dysfunction? Diabetes (2003) 52:1–8.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, HARMON J, TRAN PO, TANAKA Y, TAKAHASHI H: Glucose toxicity in 0-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes (2003) 52:581–587.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the mechanisms ofoxidative stress in islet 13-cell dysfunction.
   Google Scholar
• GRANKVIST K, MARKLUND SL, TALJEDAL TB: Cu Zn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochein. J. (1981) 199:393–398.
   PubMed Web of Science ®Google Scholar
• LENZEN S, DRINKGERN J, M: Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. (1996) 20:463–466.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, HARMON J, TRAN PO, POITOUT V: 0-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in Type 2 diabetes. Diabetes (2004) 53\(Suppl. 1):S119–S124.
   Google Scholar
• BAYNES JW: Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 40:405–412.
   PubMed Web of Science ®Google Scholar
• HUNT JV, DEAN RT, WOLFF SP: Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem. ./. (1988) 256:205–212.
   Google Scholar
• WOLFF SP, DEAN RT: Glucose autoxidation and protein modification. The potential role of `autoxidative glycosylatioff in diabetes. Biochein. J. (1987) 245:243–250.
   Google Scholar
• TANAKA Y, TRAN PO, HARMON J, ROBERTSON RP: A role for glutathione peroxidase in protecting pancreatic 0-cells against oxidative stress in a model of glucose toxicity. Proc. Natl. Acad. Sci. USA (2002) 99:12363–12368.
   PubMed Web of Science ®Google Scholar
• FRIDLYAND LE, PHILIPSON LH: Does the glucose-dependent insulin secretion itself cause oxidative stress in pancreatic 0-cells? Diabetes (2004) 53: 1942-1948.
   Google Scholar
• ••Very important review presenting evidencethat the pathway involved in glucose-mediated insulin secretion may also be responsible for generating harmful oxidative stress in the 13-cell.
   Google Scholar
• WU L, NICHOLSON W, KNOBEL SM et al.: Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. J. Biol. Chem. (2004) 279:12126–12134.
   PubMed Web of Science ®Google Scholar
• KANETO H, XU G, SONG KH et al.: Activation of the hexosamine pathway leads to deterioration of pancreatic 0-cell function through the induction of oxidative. J.Chem. (2001) 276:31099–31104.
   Google Scholar
• TAKAHASHI H, TRAN PO, LEROY E et al.: D-Glyceraldehyde causes production of intracellular peroxide in pancreatic islets, oxidative stress, and defective 0-cell function via non-mitochondrial pathways. ./. Biol. Chem. (2004) 279:37316–37323.
   PubMed Web of Science ®Google Scholar
• TIEDGE M, LORTZ S, MUNDAY R, LENZEN S: Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia (1999) 42:849–855.
   PubMed Web of Science ®Google Scholar
• IHARA Y, YAMADA Y, TOYOKUNI S et al.: Antioxidant a-tocopherol ameliorates glycemic control of GK rats, a model of Type 2 diabetes. FEBS Lett. (2000) 473:24–26.
   PubMed Web of Science ®Google Scholar
• TAJIRI Y, GRILL VE: Interactions between vitamin E and glucose on B-cell functions in the rat: an in vivo and in vitro study. Pancreas (1999) 18:274–281.
   PubMed Web of Science ®Google Scholar
• KANETO H, KAJIMOTO Y, J et al: Beneficial effects of antioxidants in diabetes: possible protection of pancreatic 0-cells against glucose toxicity. Diabetes (1999) 48:2398–2406.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, GLEASON CE, TRAN PO, HARMON JS, ROBERTSON RP: Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc. Natl. Acad. Sci. USA (1999) 96:10857–10862.
   PubMed Web of Science ®Google Scholar
• MAXWELL S, GREIG L: Anti-oxidants - a protective role in cardiovascular disease? Expert Opin. Phannacother. (2001) 2:1737–1750.
   Google Scholar
• LONN E, YUSUF S, HOOGWERF B et al: Effects of vitamin Eon cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care (2002) 25:1919–1927.
   PubMed Web of Science ®Google Scholar
• ECONOMIDES PA, KHAODHIAR L, CASELLI A et al.: The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in Type 1 and Type 2 diabetic patients. Diabetes (2005) 54:204–211.
   PubMed Web of Science ®Google Scholar
• HARDING HP, RON D: Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes (2002) 51\(Suppl. 3):5455–5461.
   Google Scholar
• •A helpful review describing ER stress and how it may be acting in the diabetic situation.
   Google Scholar
• DELEPINE M, NICOLINO M, BARRETT T et al: EIF2AK3, encoding translation initiation factor 2-a kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. (2000) 25:406–409.
   PubMed Web of Science ®Google Scholar
• HARDING HP, ZENG H, ZHANG Y et al: Diabetes mellitus and exocrine pancreatic dysfunction in perk mice reveals a role for translational control in secretory cell survival. Mol. Cell (2001) 7:1153–1163.
   PubMed Web of Science ®Google Scholar
• ••The first study to describe 13-celldysfunction and diabetes in a genetically manipulated mouse model of the ER stress response.
   Google Scholar
• LADIGES WC, KNOBLAUGH SE, MORTON JF et al.: Pancreatic 0-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58IPK. Diabetes (2005) 54:1074–1081.
   PubMed Web of Science ®Google Scholar
• NOZAKI J, KUBOTA H, YOSHIDA H et al: The endoplasmic reticulum stress response is stimulated through the continuous activation of transcription factors ATF6 and XBP1 in Ins2-IAkita pancreatic 13-cells. Genes Cells (2004) 9:261–270.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JL, SMYTH CA, BILBAO G et al: Coupling endoplasmic reticulum stress to cell death program in isolated human pancreatic islets: effects of gene transfer of Bc1-2. Transpl. Lit. (2003) 16:537–542.
   Google Scholar
• RAMANADHAM S, HSU FE ZHANG S et al: Apoptosis of insulin-secreting cells induced by endoplasmic reticulum stress is amplified by overexpression of group VIA calcium-independent phospholipase A2 1249 (iPLA2p) and suppressed by inhibition of iPLA2p. Biochemistry (2004) 43:918–930.
   PubMed Web of Science ®Google Scholar
• KITIPHONGSPATTANA K, MATHEWS CE, LETTER EH, HR: Proteasome inhibition alters glucose-stimulated (pro)insulin secretion and turnover in pancreatic 0-cells. ./. Biol. Chem. (2005) 280:15727–15734.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN S, OHSUGI M, LIU Z et al.: Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-30 in mouse insulinoma cells. Diabetes (2005) 54:968–975.
   PubMed Web of Science ®Google Scholar